With patents on reference products that treat multiple sclerosis (MS) set to expire soon in the region, a panel of experts in Latin America recently published a set of recommendations regarding the efficacy, safety, and quality of biosimilars in these countries.
With patents on reference products that treat multiple sclerosis (MS) set to expire soon in the region, a panel of experts in Latin America recently published a set of recommendations regarding the efficacy, safety, and quality of biosimilars in these countries.
As in other regions, the expanding use of biosimilars is due to interest in reducing costs, promoting the sustainability of healthcare systems, and improving patient access.
The Latin American Forum of Experts in Multiple Sclerosis gathered experts from Argentina, Bolivia, Brazil, Chile, Colombia, Costa Rica, Ecuador, Mexico, Panama, Peru, Uruguay, and Venezuela to discuss good practices and risks associated with the use of biosimilar drugs and to develop a set of recommendations as the market expands.
Each country was assessed on its approval of biosimilar drugs by regulatory agencies, use of biosimilar drugs, pharmacovigilance plans and risk management strategies, and knowledge of the latest different molecules.
The availability of MS drugs varies by country and is thus far limited to biosimilar interferons and glatiramer acetate or glatiramoids and other disease-modifying agents, including natalizumab, alemtuzumab, and ocrelizumab.
Original immunomodulatory drugs used for MS treatment have already lost their patents and newer drugs will lose their patents within the next 10 years.
However, every nation’s approval and regulatory process is different; moreover, not every country has pharmacovigilance programs that includes adverse event reporting in the post-marketing phase.
Biosimilars are in use in Argentina, Colombia, Ecuador, Mexico, and Peru, and are expected to expand to other countries in the region.
Brazil is considered to have one of the more advanced regulations regarding biosimilars, as is Argentina, a major manufacturer in Latin America. Other countries, such as Bolivia, are still developing regulations. Countries such as Chile, Mexico, and Venezuela, where foreign exchange controls are in place, are expected to expand.
The Latin American Forum of Experts in Multiple Sclerosis, an independent forum for reaching consensus about MS issues, recommends that each country:
Reference
Steinberg J, Fragoso YD, Duran Quiroz JC, et al. Practical issues concerning the approval and use of biosimilar drugs for the treatment of multiple sclerosis in Latin America [published online May 24, 2019]. Neurol Ther. doi: 10.1007/s40120-019-0139-y.
Eye on Pharma: EC Approved Ustekinumab; Zymfentra Expansion; Biosimilar Policy Briefing
September 26th 2024The European Commission (EC) approved Celltrion's ustekinumab biosimilar for chronic inflammatory diseases, Celltrion expanded access to Zymfentra (subcutaneous infliximab-dyyb) through partnerships with Cigna and Express Scripts, and the Association for Accessible Medicines held a policy briefing addressing barriers to biosimilar adoption.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
AAM Report: Despite Massive Savings, Patient OOP Costs on Biosimilars, Generics Remain High, Part 2
September 24th 2024Part 2 of our series diving into the Association for Accessible Medicines' (AAM) latest report discusses that while generics and biosimilars saved $445 billion in 2023, their potential is hindered by high patient costs, drug shortages, and ineffective policies, underscoring the need for reforms to fully realize their benefits.
French Study Finds High Patient Satisfaction With Adalimumab Biosimilar Treatment for IBD
September 21st 2024An observational study assessing patient satisfaction with adalimumab for inflammatory bowel disease (IBD) reported a high level of satisfaction with all adalimumab product, including biosimilars.